MedTrace Logo

Effective Dose of Statin Post PCI

NCT04923152 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 582

Last updated 2021-06-11

No results posted yet for this study

Summary

In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded

Conditions

  • Statin Dose

Interventions

DRUG

moderate statin dose

5 mg rosuvastatin per day

DRUG

high dose statin

40 mg rosuvastatin per day

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
52 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-01-01
Completion
2021-04-01

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923152 on ClinicalTrials.gov